Molly Klein, MD

Assistant Professor, Department of Laboratory Medicine and Pathology

Molly Klein

Contact Info

Office Phone 612-273-5848

Mailing Address:
MMC 609 Mayo
8076A (Campus Delivery Code)
420 Delaware St. SE
Minneapolis, MN 55455

Assistant Professor, Department of Laboratory Medicine and Pathology


Washington University School of Medicine, St. Louis, MO, 1994

Washington University School of Medicine (Obstetrics and Gynecology), 1994-1998

Washington University School of Medicine (Anatomic and Molecular Pathology), 2006-2009

Washington University School of Medicine (Anatomic and Molecular Pathology), 2009-2010

University of Pittsburgh School of Medicine (Breast and Gynecologic Pathology), 2010-2011

Case Western Reserve University (Anthropology), 1990


Dr. Klein is an anatomic pathologist with research interests in breast and gynecologic diseases and the application of technology to disease diagnosis, prognosis, and therapy. Klein and her colleagues conducted a study of Oncotype DX, a widely-used commercial assay for making chemotherapy decisions in estrogen receptor (ER)-positive breast cancers, to compare the combined prognostic / predictive power of standard histology and immunohistochemical markers with Oncotype DX assay. Using equations they developed, they found a strong correlation between standard pathology results and the Oncotype DX assay score. They suggested that in some if not many cases standard pathology markers plus the use of pathology-generated equations derived by linear regression analysis constitute an accurate and cost-effective substitute for the commercial assay. Klein and fellow investigators have also explored quality assurance issues concerning the Oncotype DX assay, specifically the false negatives associated with the assay’s detection of HER2 (ERBB2), an important prognostic and predictive marker in breast carcinoma.



  • Erickson BE, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, and Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecologic Oncology, 2020; 159 (1): 17-22.
  • Lou E, Vogel RI, Hoostal S, Klein M, Linden MA, Teoh D, Geller MA. Tumor-stroma proportion as a predictive biomarker of resistance to platinum-based chemotherapy in patients with ovarian cancer. JAMA Oncol. 2019 Jun 1. doi: 10.1001/jamaoncol.2019.1943.
  • Fitzpatrick M, Pulver T, Klein M, Murugan P, Khalifa M, Amin K. Perivascular Epithelioid Cell Tumor of the Uterus with Ovarian Involvement: A Case Report and Review of the Literature. Am J Case Rep. 2016 May 6; 17:309-14. 
  • Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, Bhargava R. High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study. J Clin Oncol. 2011 Nov 10;29(32):4279-85.
  • Klein ME, Dabbs DJ, Shuai Y, Bhargava R. Prediction of the Oncotype DX® Recurrence Score: Use of Equations Derived by Linear Regression Analysis. Platform presentation at the United States and Canadian Academy of Pathology 2012 Annual Meeting. Manuscript submitted for publication.
  • Klein ME, Dabbs DJ, Carter GJ, Chivukula M. An immunohistochemical panel comprised of HNF-1?, WT-1 and PAX 2 to distinguish ovarian clear cell carcinomas from ovarian serous carcinomas and metastatic renal clear cell carcinomas. Abstract accepted for United States and Canadian Academy of Pathology 2011 Annual Meeting.
  • Klein ME, Pfeifer JD, Zehnbauer BA, Stephens AL, Huettner PC. Clinical Significance of Distinguishing Homozygous from Heterozygous Complete Hydatidiform Mole. Abstract accepted for United States and Canadian Academy of Pathology 2009 Annual Meeting.
  • Aueyeung A, Klein ME, Ratts VS, Odem RR, Williams DB. Fertility treatment in the forty and older woman. J Assist Reprod Genet. 2001 Dec; 18(12):638-43.



  • Gynecologic PathologyBreast Pathology 

Board Certifications

Anatomic Pathology